<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03491605</url>
  </required_header>
  <id_info>
    <org_study_id>TJH0002017</org_study_id>
    <nct_id>NCT03491605</nct_id>
  </id_info>
  <brief_title>Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection</brief_title>
  <official_title>Study to Surveil and Track the Outcomes of Chronic Latent EBV Infection Based on Healthy Volunteers Undergoing Routine Inspection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral&#xD;
      blood will be enrolled and prospectively followed up to track the natural histories of the&#xD;
      chronic high load of EBV virus. The primary goal of this study is to explore the association&#xD;
      of peripheral high load of EBV with the hematological malignancies, and second goal is to&#xD;
      investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epstein-Barr virus (EBV) is an oncogenic virus implicated in the pathogenesis of a variety of&#xD;
      human hematological malignancies such as lymphomas, hemophagocytic lymphohistiocytosis and&#xD;
      chronic active EBV disease. While chronic latent EBV infection（especially carriers with&#xD;
      persistent high load of EBV-DNA copy number）is the gray zone between the primary infection&#xD;
      and the hematological malignancies, which is rarely concerned. Previous work has prompted the&#xD;
      heterogeneities of EBV infection, such as racial heterogeneity, viral load heterogeneity and&#xD;
      heterogeneity of infected target cells. It is of great significance to prospectively track&#xD;
      the transforming process and elucidate the association of chronic EBV infection and&#xD;
      hemophagocytic lymphohistiocytosis. Healthy subjects who was found to have high EBV-DNA load&#xD;
      （&gt;1×103 copies/ml）in peripheral blood during the physical examination were enrolled and&#xD;
      followed up by telephone or face-to-face interview periodically. The primary outcome is&#xD;
      hematological malignancies including Burkitt lymphoma, EBV+ B-cell lymphoproliferative&#xD;
      diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia&#xD;
      (ANKL), classic Hodgkin lymphoma,EBV-associated hemophagocytic lymphohistiocytosis and&#xD;
      Chronic active Epstein-Barr virus infection (CAEBV). The Exploratory purpose of this study is&#xD;
      to investigate of genetic mechanisms of immune escape and tumorigenesis of EBV infection.&#xD;
      Subgroup analysis will performed in subjects with mild high load (&gt;1×103 copies/ml and &lt;1×104&#xD;
      copies/ml) and severe high load (&gt;1×104 copies/ml) of EBV-DNA copies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hematological malignancies</measure>
    <time_frame>Five years or more if necessary</time_frame>
    <description>including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma, and Chronic active Epstein-Barr virus infection (CAEBV).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>EBV Infection</condition>
  <arm_group>
    <arm_group_label>peripheral EBV-DNA load</arm_group_label>
    <description>subjects with high load (&gt;1×103 copies/ml）of EBV-DNA copies in peripheral blood.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>peripheral EBV-DNA load</intervention_name>
    <description>No intervention</description>
    <arm_group_label>peripheral EBV-DNA load</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. perepheral blood sample of the subjects who have high load peripheral EBV-DNA&#xD;
&#xD;
        2. tumor tissues of the subjests who progress to hematological malignancies during the&#xD;
           follow-up process&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort of immunocompetent subjects with high load (&gt;1×103 copies/ml) of Epstein-Barr&#xD;
        virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to&#xD;
        track the natural histories of the chronic latent EBV infection.The subjects were enrolled&#xD;
        from healthy examers in Tongji Hospitoal attached to Huazhong University of Science and&#xD;
        Techonology. There is no limitation regarding to age and sex.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. immunocompetent subjects who was found to have high EBV-DNA load （&gt;1×103 copies/ml）in&#xD;
             peripheral blood during the physical examination&#xD;
&#xD;
          2. Willing to be followed up by telephone or face-to-face interview&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with defined immunodeficiency&#xD;
&#xD;
          2. Subjects who have taken or are going to take immunosuppressive drugs.&#xD;
&#xD;
          3. Subjects Diagnosed a validated hematopathy&#xD;
&#xD;
          4. Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy&#xD;
             is less than 1 year.&#xD;
&#xD;
          5. psychological illness which does not allow subjects to understand the study and&#xD;
             participate following his own free will&#xD;
&#xD;
          6. Pregnant woman&#xD;
&#xD;
          7. no written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianfeng Zhou, PhD.and MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Director of Department of Hematology in Tongji Hospital，HUST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Huang, PhD.and MD.</last_name>
    <phone>86-15926444318</phone>
    <phone_ext>86-83663609</phone_ext>
    <email>hj20130318@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianfeng Zhou, PhD.and MD.</last_name>
    <phone>86-13627284963</phone>
    <email>jfzhou@tjh.tjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji hospital, Tongji medical collage of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Huang, PHD</last_name>
      <phone>86-15926444318</phone>
      <email>hj20130318@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Jianfeng Zhou</investigator_full_name>
    <investigator_title>Director of Hematology,Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology</investigator_title>
  </responsible_party>
  <keyword>chronic EBV infection, hemophagocytic lymphohistiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

